Two mRNA-based COVID-19 vaccine candidates produced by Chinese manufacturer CanSino Biologics have proven effective in preclinical trials, suggesting the potential for human tests, according to a new study published in the journal Emerging Microbes & Infections.<\/p>\n\n\n\n
Results showed that the two vaccines, the mRNA-Beta and mRNA-Omicron, can induce high-titer neutralising antibody levels against original and multiple SARS-CoV-2 variants, such as Beta, Delta and Omicron, reported the Chinese news agency, Xinhua.<\/p>\n\n\n\n
Two doses of mRNA-Beta could induce broad protection especially for Beta and original variants. Meanwhile, mRNA-Omicron was suggested as a booster injection in mice vaccinated with primary mRNA-Beta or Ad5-nCoV, the company’s recombinant COVID-19 vaccine, to offer further protection against Omicron variant, according to the study.<\/p>\n\n\n\n
The Chinese mRNA vaccines got clinical trial approval in April and they have entered phase-1 human trials, according to a company statement released this week.<\/p>\n\n\n\n
Compared with traditional vaccine technologies, the mRNA technology has the advantage of a shorter development and production cycle.<\/p>\n\n\n\n
The Chinese vaccine maker said an industrialisation base of the COVID-19 mRNA vaccine was under construction in Shanghai. It will enable the annual production capacity to reach 100 million doses by the end of 2022.<\/p>\n","protected":false},"excerpt":{"rendered":"
Two mRNA-based COVID-19 vaccine candidates produced by Chinese manufacturer CanSino Biologics have proven effective in preclinical trials, suggesting the potential for human tests, according to a new study published in the journal Emerging Microbes & Infections. Results showed that the two vaccines, the mRNA-Beta and mRNA-Omicron, can induce high-titer neutralising antibody levels against original and …<\/p>\n","protected":false},"author":2,"featured_media":46896,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-46895","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-news"],"_links":{"self":[{"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/posts\/46895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/comments?post=46895"}],"version-history":[{"count":1,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/posts\/46895\/revisions"}],"predecessor-version":[{"id":46897,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/posts\/46895\/revisions\/46897"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/media\/46896"}],"wp:attachment":[{"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/media?parent=46895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/categories?post=46895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.uaebarq.ae\/en\/wp-json\/wp\/v2\/tags?post=46895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}